Inhibrx Biosciences, Inc. reported on October 23, 2025, positive results from its ChonDRAgon study showing that ozekibart significantly improved progression-free survival in chondrosarcoma patients (median PFS: 5.52 months vs. 2.66 months for placebo). The study involved 206 patients and the company plans to submit a biologics application to the FDA by Q2 2026.